leadf
logo-loader
viewZelira Therapeutics Ltd

Zelira Therapeutics forms exclusive licensing deal to distribute its HOPE products in Washington DC

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) Managing Directors Dr Oludare Odumosu and Dr Richard Hopkins tell Proactive the group has entered into a binding licensing agreement with Alternative Solutions LLC to manufacture and distribute Zelira’s HOPE products in the Washington DC approved medical cannabis market.

Dr Odumosu and Dr Hopkins explain Washington DC is a gateway territory, with over 24 million visitors passing through each year. Alternative Solutions will commercialize Zelira’s HOPE products for sale in the second quarter of 2021.

Quick facts: Zelira Therapeutics Ltd

Price: 0.099 AUD

ASX:ZLD
Market: ASX
Market Cap: $117.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Zelira Therapeutics and Emyria team up for 'disruptive' autism spectrum...

Zelira Therapeutics Ltd's (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) Richard Hopkins and Emyria Ltd's (ASX:EMD) Michael Winlo speak to Proactive's Andrew Scott after announcing they've entered into an agreement to conduct an observational trial for patients diagnosed with autism spectrum disorder (ASD)...

on 10/11/20

2 min read